Klaudia Dąbkowska, Magdalena Wojdas, Katarzyna Winsz-Szczotka

Juvenile idiopathic arthritis – diagnostic and therapeutic procedures
2019-01-31

Juvenile idiopathic arthritis (JIA) is a heterogeneous group of autoimmune or autoinflammatory joint diseases that may contribute to the disability of an afflicted child, due to disturbances in the structure and function of the osteoarticular system. The etiopathogenesis of JIA is a complex and not fully understood. Initiation of the inflammatory process, which underlying the discussed pathology, is under influence of genetic predisposition and adverse environmental factors. The inflammation, in its aggressive course, quickly leads to significant structural and functional changes in the osteoarticular system. Therefore, it is important to introduce effective pharmacotherapy, which protects the patient against the development of disability. Guidelines for the pharmacotherapy of children with JIA include the use of non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticosteroids, diseasemodifying anti-rheumatic drugs (DMARDs) and biological treatment. Currently, there is no fully effective treatment for JIA, so it is crucial to find drugs, or a combination of drugs, that have significant therapeutic efficacy.

Keywords: juvenile idiopathic arthritis, non-steroidal anti-inflammatory drugs, glucocorticosteroids, disease-modifying anti-rheumatic drugs, biological treatment.

© Farm Pol, 2019, 75 (1): 34–43